NYHET! To injeksjoner ved oppstart med Abilify Maintena® (aripiprazol)

Les mer: Abilify Maintena SPC

Les mer: RXULTI® SPC




Referanser for innhold på denne siden (inkludert videoen med Bjørn Fjeldstad):

1. Abilify Maintena® SPC 10/2020 avsnitt 4.2. 
2. Tiihonen J, Haukka J, Taylor M. A Nationwide Cohort Study of Oral and Depot Antipsychotics After First Hospitalization for Schizophrenia Am J Psychiatry 2011;168:603–609.
3. Abilify Maintena® SPC 10/2020, avsnitt 4.8.
4. Fleischhacker WW, Sanchez R, Perry PP et al. Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. Br J Psychiatry 2014;205:135–144, 
5.Hasan A, Falkai P, Wobrock T et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry 2013;14:2-44.
6. Kane JM, Sanchez R, Perry PP et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study.  J Clin Psychiatry 2012;73:617–624.
7. Corell C, Citrome L, Haddadd PM et al. The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence. J Clin Psychiatry 2016;77(suppl 3):1-24.


Du forlater Progress in Mind
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
Informasjonen på dette nettstedet er utelukkende ment for helsepersonell
Register for access to Progress in Mind in your country